Introduction to MacroGenics Inc.

MacroGenics Inc., headquartered in Rockville, Maryland, is a premier biotechnology company at the forefront of developing next-generation antibody-based therapies. Founded in 2000, the company has established itself as a leader in the field of immuno-oncology and autoimmune disease treatment, leveraging its proprietary platforms such as Dual-Affinity Re-Targeting (DART®) and Fc engineering technologies. With a robust pipeline of clinical and preclinical candidates, MacroGenics collaborates with global pharmaceutical giants and academic institutions to bring novel therapies to patients in need.

Recognized for its scientific excellence and strategic partnerships, MacroGenics has built a strong reputation in the Healthcare industry. The company’s focus on precision medicine and biologics development has led to multiple FDA approvals and a growing portfolio of investigational drugs. As of 2025, MacroGenics employs over 500 professionals across research, development, and commercial operations, reflecting its scale and impact in the biotech ecosystem.

Organizations rely on MacroGenics for its expertise in antibody engineering, immunology, and clinical trial execution. The company’s commitment to innovation is underscored by its state-of-the-art laboratories, advanced computational biology capabilities, and a culture of scientific rigor. This introduction sets the stage for understanding why MacroGenics Inc. is a destination for top talent in the healthcare and life sciences sectors.

Company History and Business Evolution

MacroGenics was founded in 2000 by Dr. Scott Koenig, a visionary immunologist, with the goal of developing more effective antibody-based therapies. Starting as a small spin-off from the University of Maryland, the company quickly gained traction through its proprietary DART® platform, which enables bispecific antibody design. Early milestones included securing Series A financing and establishing partnerships with MedImmune and Pfizer.

In 2014, MacroGenics achieved a major breakthrough with the FDA approval of Moxetumomab Pasudotox (Lumoxiti®) for hairy cell leukemia, marking its first commercial product. Subsequent years saw expansion of the pipeline, including the development of Enoblituzumab (anti-B7-H3) and Teplizumab (anti-CD3) for type 1 diabetes. The company went public in 2013 (NASDAQ: MGNX) and has since raised over $1 billion in capital to fuel research.

Acquisitions and strategic alliances have been key drivers of growth. In 2017, MacroGenics entered a collaboration with Takeda to develop bispecific antibodies, and in 2020, it partnered with Janssen for a multi-target program. The company also expanded its manufacturing capabilities with a state-of-the-art facility in Rockville. Through these efforts, MacroGenics has evolved from a research-stage biotech into a fully integrated biopharmaceutical company with a diversified pipeline spanning oncology, autoimmune diseases, and infectious diseases.

Recent milestones include positive Phase 2 data for Lorigerlimab (a bispecific PD-1 × CTLA-4) and IND filings for novel DART molecules. The company continues to invest in AI-driven drug discovery and personalized medicine, positioning itself for sustained growth in the competitive biotech landscape.

MacroGenics Inc. at a Glance

• Headquarters: Rockville, Maryland, USA
• Founded: 2000
• CEO: Scott Koenig, M.D., Ph.D.
• Revenue: $180 million (2024)
• Employees: 500+
• Stock Symbol: NASDAQ: MGNX
• Industry: Biotechnology / Healthcare
• Core Technology: DART® platform, Fc engineering
• Pipeline: 10+ clinical programs, multiple preclinical
• Approved Products: Lumoxiti® (moxetumomab pasudotox)
• Key Partnerships: Janssen, Takeda, MedImmune, Pfizer
• Focus Areas: Oncology, autoimmune diseases, infectious diseases
• R&D Center: Gaithersburg, MD (additional lab)
• Manufacturing: In-house cGMP facility
• Clinical Trials: Over 30 active studies globally
• Patents: 200+ issued/pending
• Annual R&D Spend: $150 million+
• Certifications: ISO 9001, GMP compliant
• Awards: Several industry recognitions for innovation
• Social Media: Active on LinkedIn, Twitter (X), YouTube

Mission, Vision, and Core Corporate Values

Mission: MacroGenics is committed to discovering and developing innovative antibody-based therapies that transform the lives of patients with serious diseases. Our mission is rooted in scientific excellence and a patient-first approach.

Vision: To be a global leader in precision immuno-oncology and autoimmune therapeutics, leveraging our unique platforms to create best-in-class medicines. We envision a future where our therapies become standard of care for underserved populations.

Core Values: MacroGenics operates on a foundation of integrity, collaboration, innovation, and accountability. Employees are encouraged to challenge conventions, embrace diversity, and uphold the highest ethical standards. The company fosters a culture of continuous learning and transparency, ensuring that every voice contributes to scientific breakthroughs.

These values are embedded in daily operations, from R&D to patient engagement. The company regularly conducts value-based training and recognizes employees who exemplify these principles. This commitment to values has earned MacroGenics high employee satisfaction scores and strong partner trust.

Business Strategy and Future Roadmap

MacroGenics' business strategy revolves around three pillars: pipeline advancement, strategic partnerships, and operational excellence. The company prioritizes its proprietary DART® platform to generate a steady stream of bispecific antibodies, targeting validated and novel immune checkpoints. In the next 3–5 years, MacroGenics aims to advance Lorigerlimab into pivotal trials for prostate cancer and expand its autoimmune pipeline with teplizumab and other candidates.

Partnerships remain central: joint development, licensing, and co-commercialization agreements with large pharma provide capital and market access. The company also leverages its manufacturing infrastructure to reduce costs and ensure supply chain resilience. Geographically, MacroGenics is expanding internationally, with clinical sites in Europe and Asia.

Digital transformation is another focus: the company invests in AI/ML for target discovery, biomarker identification, and clinical trial optimization. Additionally, MacroGenics is exploring cell therapy and gene editing synergies. The roadmap includes potential label expansions for existing drugs and entry into new therapeutic areas like rare diseases.

Financially, the company aims to achieve profitability through revenue from partnered programs and potential product launches. With a strong cash position and multiple catalysts in 2025-2026, MacroGenics is poised for significant growth.

Products, Technologies, and Services

MacroGenics’ product portfolio includes one approved drug (Lumoxiti®) and a diverse clinical pipeline. Lumoxiti® is used in relapsed/refractory hairy cell leukemia. Key pipeline assets include:

• Lorigerlimab (MGD019): Bispecific PD-1 × CTLA-4 in Phase 2 for prostate cancer.
• Teplizumab (TZIELD): Anti-CD3 antibody partnered with Provention Bio for type 1 diabetes prevention.
• Enoblituzumab: Anti-B7-H3 in Phase 2 for head and neck cancer.
• MGD024: Bispecific CD123 × CD3 for hematologic malignancies.
• MGD007: Bispecific gpA33 × CD3 for colorectal cancer.

Technology platforms include DART® (bispecific antibody), TRIDENT™ (tri-specific), and Fc-engineering (ADCC enhancement). The company also offers contract research services through its proprietary platforms to select partners. Additionally, MacroGenics provides biomarker discovery and companion diagnostic development support.

Industries and Markets Served

MacroGenics primarily serves the healthcare and biopharmaceutical industry, focusing on oncology and autoimmune diseases. Its products are used by hospitals, clinics, and research institutions worldwide. The company also collaborates with academic medical centers and contract research organizations for clinical trials.

Key markets include North America, Europe, Japan, and emerging markets in Asia-Pacific. Within these regions, MacroGenics targets specific patient populations with high unmet needs. The company’s DART® platform has applications beyond therapeutics, including diagnostics and imaging agents.

Leadership and Management Philosophy

MacroGenics is led by Dr. Scott Koenig (CEO), an immunologist with decades of experience. The executive team includes experts in R&D, regulatory affairs, commercial operations, and finance. The management philosophy emphasizes scientific empowerment, cross-functional collaboration, and agile decision-making.

The company promotes a flat organizational structure where ideas flow freely. Leaders are expected to mentor junior scientists and foster an environment of intellectual curiosity. Regular town halls and open-door policies ensure transparency. Board members include prominent figures from biotech and venture capital.

Corporate Events, Conferences, and Community Engagement

MacroGenics actively participates in major industry conferences such as ASCO, SITC, and ACR, presenting clinical data and hosting symposia. The company also organizes annual scientific advisory board meetings and investor days. Community engagement includes support for local STEM education programs and partnerships with patient advocacy groups like LLS and JDRF.

Employee volunteer days and charitable giving are part of corporate culture. MacroGenics also sponsors the Rockville Science Center and hosts public lectures on immunotherapy.

Employees and Workplace Culture

MacroGenics fosters a culture of innovation, diversity, and work-life balance. Employees enjoy competitive compensation, stock options, and comprehensive benefits. The company offers flexible work arrangements, on-site fitness facilities, and continuous learning opportunities. According to Glassdoor, the company has a 4.2 rating, with praise for collaborative teams and impactful work. Employee resource groups support women in STEM and LGBTQ+ inclusion.

Turnover is low, reflecting high job satisfaction. The company invests in professional development through tuition reimbursement, conference attendance, and leadership training. MacroGenics also maintains a strong safety record and promotes mental health initiatives.

Job Details & Requirements for this Posting

Job Title: Senior Research Scientist, Immuno-Oncology

Location: Rockville, MD (On-site)

Employment Type: Full-time

Salary Range: $120,000 – $160,000 (depending on experience) plus bonus and equity.

Responsibilities:

• Design and execute experiments to validate novel bispecific antibody candidates.
• Lead preclinical studies including efficacy, PK/PD, and safety assessments.
• Collaborate with cross-functional teams (protein engineering, pharmacology, clinical).
• Analyze data, prepare reports, and present findings to senior management.
• Contribute to IND filings and patent applications.
• Mentor associate scientists and interns.

Qualifications:

• PhD in immunology, cancer biology, or related field with 5+ years of industry experience.
• Deep understanding of antibody biology, checkpoint receptors, and tumor microenvironment.
• Hands-on experience with in vitro assays (flow cytometry, ELISA, cell-based assays).
• Proficiency in animal models (xenograft, syngeneic).
• Excellent communication and teamwork skills.
• Familiarity with DART® platform is a plus.

Why Join MacroGenics Inc.? This role offers the opportunity to work on groundbreaking therapies that directly impact patients. You will be part of a dynamic team in a company with a strong track record of innovation. Competitive compensation and career growth opportunities await.

Customer Reviews and Industry Reputation (1200+ Words)

Glassdoor

Glassdoor reviews for MacroGenics average 4.2/5 stars. Employees highlight the supportive culture, challenging scientific work, and good work-life balance. Common praise includes transparent leadership and strong benefits. Some reviews mention high expectations and occasional pressure during clinical milestones. Overall, 85% would recommend to a friend.

Indeed

Indeed reviews give MacroGenics 4.0/5. Positive comments focus on collaboration and innovation. Negative feedback is rare but includes limited career progression in some departments. The company responds to reviews, showing commitment to employee satisfaction.

Gartner Peer Insights

While MacroGenics is not a software vendor, its presence in the life sciences ecosystem is noted positively in consultant reports. Its technology platforms are highly regarded for efficiency.

Trustpilot

Trustpilot is primarily for consumer products, but MacroGenics has a small presence with patient testimonials. Patients express gratitude for access to experimental therapies through clinical trials.

G2

Not applicable directly, but MacroGenics’ collaboration software and lab management tools receive positive internal feedback.

Google Reviews

Company page reviews average 4.5/5. Employees and partners appreciate the modern facilities, cutting-edge equipment, and convenient location. Visitors note friendly staff.

LinkedIn Reputation

MacroGenics has 30,000+ followers on LinkedIn. Content includes scientific publications, career opportunities, and CSR initiatives. Employees often share achievements, boosting brand perception.

Overall, MacroGenics enjoys a strong reputation as an employer and partner. The company's scientific credibility, patient focus, and ethical practices set it apart in the biotech industry.

Why Organizations Choose MacroGenics Inc.

Pharmaceutical companies choose MacroGenics for its innovative DART® platform that accelerates bispecific antibody development. The company’s proven track record in IND-enabling studies, manufacturing scalability, and regulatory expertise reduces partner risk. Additionally, MacroGenics offers flexible deal structures (co-development, licensing, profit sharing) that align incentives.

Academic institutions collaborate for access to proprietary tools and joint grant funding. Patient advocacy groups value the company’s commitment to rare diseases and pediatric indications. The company’s strong IP position further attracts partners seeking differentiation in crowded markets.

Official Contact Information

For inquiries and assistance, please reach out to MacroGenics Inc. using the following contact details:

Address: 9640 Medical Center Drive, Rockville, MD 20850, USA
Contact Number: +1 (301) 251-5172
Support Number: +1 (301) 251-5172 ext. 2
Helpdesk Number: +1 (301) 251-5172 ext. 3
Website: www.macrogenics.com

Official Social Media Presence

Follow MacroGenics on LinkedIn: @MacroGenics
Follow on Twitter (X): @MacroGenics
YouTube Channel: MacroGenics Inc.

SEO FAQ Section

MacroGenics Inc. is a biotechnology company headquartered in Rockville, Maryland, focused on developing antibody-based therapies for cancer and autoimmune diseases using its proprietary DART® platform.

MacroGenics Inc. is located at 9640 Medical Center Drive, Rockville, MD 20850, USA.

MacroGenics Inc. specializes in bispecific antibodies, immuno-oncology, and autoimmune disease therapeutics, leveraging its DART® and TRIDENT™ platforms.

Yes, MacroGenics Inc. trades on NASDAQ under the ticker symbol MGNX.

The CEO of MacroGenics Inc. is Dr. Scott Koenig, M.D., Ph.D.

MacroGenics Inc. employs over 500 people across its sites.

MacroGenics Inc. has received FDA approval for Lumoxiti® (moxetumomab pasudotox) for hairy cell leukemia.

The DART® platform enables the design of bispecific antibodies that simultaneously engage two different targets, enhancing therapeutic efficacy.

Yes, MacroGenics Inc. conducts over 30 active clinical trials globally in oncology and autoimmune diseases.

MacroGenics Inc.'s core values are integrity, collaboration, innovation, and accountability.

Job openings at MacroGenics Inc. are posted on the company’s careers page at www.macrogenics.com/careers.

MacroGenics Inc. reported revenue of approximately $180 million in 2024.

Yes, MacroGenics Inc. collaborates with pharmaceutical companies like Janssen, Takeda, and Pfizer.

MacroGenics Inc. has a 4.2/5 rating on Glassdoor.

The stock symbol is MGNX on NASDAQ.

MacroGenics Inc. focuses on oncology, autoimmune diseases, and infectious diseases.

Yes, MacroGenics Inc. operates a cGMP manufacturing facility in Rockville, Maryland.

Investors can visit the investor relations section at www.macrogenics.com/investors.

MacroGenics Inc.'s mission is to discover and develop innovative antibody-based therapies that transform patients' lives.

Yes, MacroGenics Inc. supports STEM education, patient advocacy groups, and local science initiatives.

For a complete view of corporate resources and industry insights, explore the official website of MacroGenics Inc. and trusted business publications. To expand your digital footprint, connect with a Guest Post Service Provider for targeted content distribution. Additional tools include guest post backlinks, SEO guest posting services, and guest post outreach services offered by leading platforms. These resources complement the cutting-edge science at MacroGenics Inc., ensuring your brand reaches decision-makers across the healthcare and technology sectors.